)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Delcath Systems
Delcath Systems (DCTH) investor relations material
Delcath Systems Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary6 Aug, 2026
Executive summary
Q2 2026 total revenue reached $29.1M, up from $24.2M in Q2 2025, driven by HEPZATO KIT sales of $27.1M and CHEMOSAT revenue of $2M.
Net income was $2.7M for Q2 2026, unchanged from Q2 2025.
31 active treatment centers, with plans to reach 37 by year-end, and approximately 30% HEPZATO volume growth.
Commercial execution in metastatic uveal melanoma is funding expansion into other liver-dominant cancers, with ongoing Phase 2 trials in colorectal and breast cancer.
CHEMOSAT is approved and reimbursed in Europe, with recent MDR certification and positive clinical trial results.
Financial highlights
Gross margin reached 90% in Q2 2026, up from 86% in Q2 2025; full-year guidance is 86%-89%.
Adjusted EBITDA was $7.6M in Q2 2026, down from $9.8M in Q2 2025.
Cash and investments totaled $95.9M as of June 30, 2026, with $5.7M cash provided by operations and no debt.
Research & development expense was $10.4M in Q2 2026, up from $6.9M; SG&A expense was $13.4M, up from $11.4M.
Basic and diluted EPS for Q2 2026 were $0.07.
Outlook and guidance
Full-year 2026 revenue guidance raised to $104M-$108M, reflecting at least 28% HEPZATO KIT volume growth over 2025.
Positive adjusted EBITDA projected for the full year.
Guidance reflects strong H1 performance and reduced expected seasonality in H2.
Current cash, equivalents, and investments expected to support operations for at least 12 months.
R&D expenses expected to increase as Phase 2 trials progress.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Delcath Systems
- Q1 2026 revenue up 26% to $25M, with $100M+ guidance and strong HEPZATO KIT growth.DCTH
Q1 2026 - Virtual annual meeting to vote on directors, equity plan, auditor, and executive pay.DCTHProxy filing
- Annual meeting to vote on directors, equity plan, auditor, and executive pay, all Board-recommended.DCTHProxy filing
- Record $85.2M revenue, positive net income, and strong 2026 growth outlook.DCTHQ4 2025
- Registration allows up to $150M in securities to fund oncology growth and operations.DCTHRegistration Filing
- Board recommends approval of all proposals, including director elections and plan amendments.DCTHProxy Filing
- Virtual Annual Meeting to vote on directors, equity plans, auditor, and executive pay.DCTHProxy Filing
- Q2 revenue hit $7.8M with 80% margin; net loss widened, but U.S. growth and NTAP boost outlook.DCTHQ2 2024
- Q3 revenue hit $11.2M, net income $1.9M, and $25M raised from warrants; all debt eliminated.DCTHQ3 2024
Next Delcath Systems earnings date
Q3 20269 Nov, 2026
Delcath Systems
Next Delcath Systems earnings date
Q3 20269 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Delcath Systems Inc. is a medical technology company focused on the development and commercialization of innovative therapies for cancers with limited treatment options. The company specializes in targeted drug delivery systems, designed to isolate and deliver high doses of chemotherapy to specific organs or regions while minimizing systemic exposure. The company is headquartered in Wilmington, Delaware, and its shares are listed on the NASDAQ.